Physician profile
Muneel Abbas
NPI 1740404375
$3,970.25
in general payments reported to CMS, 2019-2025
33 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $282 · 2021: $956 · 2022: $933 · 2023: $346 · 2024: $731 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $676.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $518.10 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $467.63 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $287.19 | 2021-2025 | |
| Abbott Laboratories | $186.48 | 2021-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.62 | 2019-2024 | Xifaxan |
| Pfizer INC. | $136.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.44 | 2019-2022 | |
| Lilly USA, LLC | $129.26 | 2020-2025 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $125.72 | 2020-2022 | |
| Insmed, INC. | $106.43 | 2022-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $104.56 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $82.82 | 2021 | |
| Amgen INC. | $82.28 | 2019-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $78.28 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $76.18 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $75.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $71.35 | 2021-2023 | Trelegy Ellipta |
| Dexcom, INC. | $65.94 | 2021-2024 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $59.85 | 2025 | Ohtuvayre |
| Daiichi Sankyo INC. | $49.70 | 2022 | |
| Esperion Therapeutics, INC. | $46.70 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.66 | 2024-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $34.72 | 2022-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.62 | 2022 | |
| Allergan, INC. | $30.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2023 | Invega Trinza, Invega Sustenna |
| Kyowa Kirin, INC. | $18.32 | 2024 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2020 | |
| Recordati_rare_diseases_inc. | $15.29 | 2021 | |
| Sumitomo Pharma America, INC. | $14.67 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $13.11 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneel Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.